Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olokizumab in Severe COVID-19
NCT04452474Phase 3Withdrawn
- Sponsor
- R-Pharm
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of olokizumab in coronavirus disease 2019 (COVID-19), sponsored by R-Pharm. Planned start Jun 2020; status: withdrawn.
02
Drugs
olokizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04452474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04452474.